Pay in 4 interest-free payments of $5.49 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
This hegemony is about to be permanently disrupted by a new mass market, chronic disease area, which unusually is seeing very high levels of out of pocket spend- in February 2024, Novo Nordisks CEO noted that in Europe, 80% of Wegovy sales so far were paid for out of pocket by patients- showing, against preconception, that European patients were as willing as Americans to pay for their own obesity medications 5
This is why "eat less, move more" fails
The FDA-approved weight loss treatment, tirzepatide (also known as Zepbound), is here to make a significant difference
the Certificate of Analysis is published on this page
US$ 27.91
US$ 29.10
US$ 27.72
US$ 23.82
